Litcius/Paper detail

Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial

Jesús Argente, Charles F. Verge, Uzoma Okorie, Ilene Fennoy, Megan M. Kelsey, Casey Cokkinias, Cecilia Scimia, Hak‐Myung Lee, I. Sadaf Farooqi

2024The Lancet Diabetes & Endocrinology40 citationsDOI

Topics & Concepts

MedicineOpen labelObesityMulticenter studyPediatricsClinical trialInternal medicinePhysical therapyRandomized controlled trialRegulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism
Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial | Litcius